Cure8 trial brief
This study examines a combination of ustekinumab plus low‑dose upadacitinib for patients with refractory Crohn’s disease — a group with limited options after failing anti‑TNF and single‑agent therapy. Results could inform clinicians about short‑term effectiveness and safety of this real‑world strategy.
Patients with refractory Crohn's disease, clinicians treating IBD, and researchers studying combination biologic/small‑molecule therapies or real‑world outcomes.
The study is observational and retrospective — researchers collected existing medical-record data from several IBD centers in China for patients treated between July 2023 and December 2025.
The combination regimen started with intravenous ustekinumab re‑induction followed by subcutaneous maintenance plus oral low‑dose upadacitinib (15 mg or 30 mg daily) for at least 12 weeks, with outcomes assessed at weeks 12–16 (clinical) and up to week 24 (endoscopy and safety).
The report describes inclusion and exclusion criteria, planned primary outcome (clinical remission by HBI ≤4 at week 12–16), cohort size target (planned enrollment 84), and safety-related exclusion criteria (active serious infection, malignancy, thromboembolism risk, pregnancy).
Because this is a retrospective real‑world cohort rather than a randomized trial, treatment was not assigned by the study but documented from clinical practice.
Retrospective, real‑world design: data were collected from existing records and no interventions were assigned by the study. Registry entry lists planned outcomes and safety exclusions but does not equal a peer‑reviewed publication of results.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
The article summarizes recent drug approvals and Phase 3 trial results that could affect which biologic treatments are available and how the Crohn's disease treatment market may change. It also gives epidemiology and...
